Sensible Biotechnologies, a biotechnology company developing cell-based manufacturing technologies for mRNA medicines, has raised $47 million to advance and scale its platform. The financing includes a Series A and up to $20 million in non-dilutive funding from Slovakia and the European Union. The company said the funding will support the development and scale-up of its VECTOR platform, expansion of its AI-enabled mRNA design and high-throughput screening capabilities, and development of clinica

Matchpoint Therapeutics announced Wednesday the closing of a series B financing round that has added $150 million to the biotech's coffers in support of efforts to develop oral, small-molecule drugs for autoimmune and inflammatory diseases. The financing was co-led by Nextech Invest and Norwest, with new participants including Invus, BB Biotech, T1D Fund and BOLD Longevity Growth. In addition, existing investors Access Biotechnology, Atlas Venture, Sanofi Ventures and Digitalis Ventures also to

TCGX today announced the closing of the TCGX Asia Life Sciences Fund I, an oversubscribed $600 million investment vehicle backed by a diverse group of international institutional investors. The fund will focus on investing in innovative biotechnology companies based in Asia. In connection with the launch of TCGX Asia Life Sciences Fund I, L.P., TCGX is expanding its operations to Asia with new offices in Hong Kong and Shanghai to take advantage of the explosive growth of early-stage drug discov

Kovina Therapeutics Inc., a biotechnology company developing first-in-class small molecule therapeutics targeting the Human Papillomavirus (HPV) E6 oncoprotein, today announced a $2.3 million Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI). The two-year award will support IND-enabling development of Kovina’s lead oral small molecule program for HPV-driven cancers. The award follows Kovina’s recent publication in the Proceedings of the N

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment will help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the treatment of B-cell malignancies. Under the terms

UK-based Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN biological foundation models and advance AI-designed therapies towards clinical development. S32 led the oversubscribed financing round. Investors included Catalio Capital Management, European Tech Collective, and Firebrand River Capital. Other backers were Nvidia, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. The company said the late

Five-year NIH-funded program supports preclinical research, drug product manufacturing, regulatory preparation, and planned clinical studies, advancing MTTI’s EvaThera™ platform and oncology pipeline Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company, today announced that it has been awarded a $3.17 million, five-year National Cancer Institute (NCI) grant to advance the development of ¹⁷⁷Lu-EBRGD, an investigational radiopharmaceutical targeting integrin

Envisagenics’ platform makes use of AI to screen and detect cancer-specific RNA alterations, which Boehringer Ingelheim wants to target through various precision treatment modalities, including multi-specific antibodies, antibody-drug conjugates and T cell engagers. Boehringer Ingelheim is partnering with Envisagenics to leverage the biotech’s AI-forward approach to RNA splicing—a particular molecular alteration in cancer that the companies claim is “one of the last largely untapped sources” of

NIH-supported research will evaluate the mechanistic effects of fosamprenavir and support a Phase II randomized, double-blind, placebo-controlled clinical trial in patients with PPI-refractory GERD N-Zyme Biomedical Inc. (“N-Zyme”), a clinical-stage biotechnology company developing novel pepsin-targeted therapies for reflux disease, today announced that a research team led by N-Zyme Co-Founder and Chief Scientific Officer Dr. Nikki Johnston has been awarded US$2.76 million through an R01 resear

Round Led by .406 Ventures Fuels Teal Health's Next Phase of Growth, Expanding Payor, Health System, Employer and Provider Partnerships Ahead of Broad Insurance Coverage in 2027 Sept. 22, 2026 -- Teal Health, creators of the Teal Wand™, the first and most accurate FDA-authorized self-collection device for at-home HPV cervical cancer screening, today announced $22 million in Series A funding to meet accelerating consumer demand and expand access ahead of broad insurance coverage beginning in Ja